Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is a potentially exciting opportunity for investors seeking exposure to the rapidly growing oncology market with an innovative precision medicine approach. With multiple clinical-stage assets including darovasertib, IDE397, IDE849, IDE275, IDE161, and IDE705, IDEAYA has a diverse pipeline with the potential for multiple future revenue streams. The recent positive topline results from the pivotal Ph. 2/3 OptimUM-02 study for darovasertib suggest a significant potential for off-label use in HLA-A*02:01-positive metastatic uveal melanoma (mUM) patients, representing a $150M additional TAM opportunity.

Bears say

IDEAYA Biosciences is an oncology-focused precision medicine company with a diverse pipeline of clinical and preclinical product candidates. While its approach of integrating small molecule drug discovery with biomarker identification is promising, the company is not yet generating any revenue from its products. Additionally, the company's current valuation appears overinflated, with a DCF analysis estimating a value of only $54 per share, indicating potential downside risk for investors.

IDYA has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 14 analysts, IDYA has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.